339 related articles for article (PubMed ID: 20959960)
1. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.
Confavreux CB; Chapurlat RD
Osteoporos Int; 2011 Apr; 22(4):1023-36. PubMed ID: 20959960
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapies and bone loss in rheumatoid arthritis.
Zerbini CAF; Clark P; Mendez-Sanchez L; Pereira RMR; Messina OD; Uña CR; Adachi JD; Lems WF; Cooper C; Lane NE;
Osteoporos Int; 2017 Feb; 28(2):429-446. PubMed ID: 27796445
[TBL] [Abstract][Full Text] [Related]
3. [Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis].
Głuszko P
Endokrynol Pol; 2009; 60(2):115-21. PubMed ID: 19396755
[TBL] [Abstract][Full Text] [Related]
4. The effect of biologic agents on bone homeostasis in chronic inflammatory rheumatic diseases.
Di Munno O; Ferro F
Clin Exp Rheumatol; 2019; 37(3):502-507. PubMed ID: 30557124
[TBL] [Abstract][Full Text] [Related]
5. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
6. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
Shan J; Zhang J
Joint Bone Spine; 2019 Mar; 86(2):173-183. PubMed ID: 29635017
[TBL] [Abstract][Full Text] [Related]
7. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
8. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
9. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases.
Kádár G; Balázs E; Soós B; Laduver A; Keszthelyi P; Szekanecz Z; Kovács L
Clin Rheumatol; 2014 Mar; 33(3):329-33. PubMed ID: 24497172
[TBL] [Abstract][Full Text] [Related]
10. Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.
Soós B; Szentpétery Á; Raterman HG; Lems WF; Bhattoa HP; Szekanecz Z
Nat Rev Rheumatol; 2022 May; 18(5):249-257. PubMed ID: 35273387
[TBL] [Abstract][Full Text] [Related]
11. [Inflammatory rheumatic diseases].
Kellner H
MMW Fortschr Med; 2009 Apr; 151(14):67-70; quiz 71. PubMed ID: 19504844
[No Abstract] [Full Text] [Related]
12. Use of rituximab to treat a patient with coexistence of rheumatoid arthritis and ankylosing spondylitis: 18 months follow-up.
Dundar U; Çevik H; Demirdal US; Toktas H
Int J Rheum Dis; 2018 Oct; 21(10):1869-1872. PubMed ID: 24618052
[TBL] [Abstract][Full Text] [Related]
13. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
14. Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients' Adherence Using a Self-report Questionnaire.
Betegnie AL; Gauchet A; Lehmann A; Grange L; Roustit M; Baudrant M; Bedouch P; Allenet B
J Rheumatol; 2016 Apr; 43(4):724-30. PubMed ID: 26879361
[TBL] [Abstract][Full Text] [Related]
15. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
16. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
[TBL] [Abstract][Full Text] [Related]
17. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
[TBL] [Abstract][Full Text] [Related]
18. The use of biologic therapies in the treatment of rheumatoid arthritis.
Wang D; Li Y; Liu Y; Shi G
Curr Pharm Biotechnol; 2014; 15(6):542-8. PubMed ID: 25213363
[TBL] [Abstract][Full Text] [Related]
19. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
Lanfant-Weybel K; Lequerré T; Vittecoq O
Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
[TBL] [Abstract][Full Text] [Related]
20. Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy.
Ruwaard J; VAN DER Vlugt ER; Wolbink G
J Rheumatol; 2019 Jan; 46(1):117-118. PubMed ID: 30323005
[No Abstract] [Full Text] [Related]
[Next] [New Search]
